Incyte poised to sell more than $700 million in stock

Photo courtesy WHYY Newsworks

Incyte Corporation,Wilmington, announced the pricing of its underwritten public offering of 4,945,000 shares of its common stock. The company has granted the underwriter an option to purchase up to an additional 741,750 shares of common stock.

Based on the current stock price, the offering could raise more $700 million.

According to a release, the company intends to use the net proceeds from the offering for general corporate purposes, including working capital, research and development activities, capital expenditures and potential strategic transactions.

The underwriter intends to offer the shares from time to time for sale in one or more transactions on The NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale,


BofA Merrill Lynch is acting as the sole underwriter of this offering.

Incyte has been working to build off the success of its blood cancer drug Jakafi with a promising research development pipeline.

The company is currently expanding its headquarters and research center on Augustine Cutoff just outside the city of Wilmington.

Facebook Comments
Previous articleSimulcast to outline energy assistance options for business
Next articleAstraZeneca reports promising results from lung cancer drug trials
Delaware Business Now is a four-year-old, five-day-a-week newsletter and website operated by Bird Street Media LLC. Publisher and Chief Content Officer is Doug Rainey, a 30-year veteran of business journalism in the state of Delaware.  Business Now focuses on breaking business news in Delaware and immediate adjacent areas with apropriate background and perspective. Also offered exclusively in our FREE newsletter is commentary on state and regional issues. Have a complaint, question or even a compliment? Send an email to For advertising information, click on the About tab at the top of the home page Our business hours are 8 a.m. to 5 p.m., Monday through Friday. Call us at 302.753.0691.